Introduction Retrospective studies have shown immune-related adverse events (irAEs) to
be associated with better prognosis. However, no prospective clinical trials have been …

Importance Although treatment with first-generation epidermal growth factor receptor (EGFR)–tyrosine
kinase inhibitor (TKI) plus antiangiogenic inhibitor has shown promising efficacies …

Introduction To evaluate the efficacy and safety of osimertinib plus bevacizumab for
previously untreated patients with advanced nonsquamous NSCLC harboring EGFR-sensitizing …

According to rapid development of chemotherapy in advanced non-small cell lung cancer (NSCLC),
the Japan Lung Cancer Society has been updated its own guideline annually since …

Concurrent chemoradiation therapy (CCRT) is the treatment of choice for locally advanced
non-small cell lung cancer (LA-NSCLC). Several clinical trials that combine programmed cell …

Considering the increasing number of identified driver oncogene alterations, additional
genetic tests are required to determine the treatment for advanced non‐small‐cell lung cancer (…

Objectives The incidence of real-world pneumonitis and durvalumab rechallenge during
chemoradiotherapy and durvalumab consolidation for non-small cell lung cancer is unknown. …

BACKGROUND: Early enteral nutrition is recommended for mechanically ventilated patients
in several studies and guidelines. In contrast, the effects of early enteral nutrition on …

Background Although predictive value of immune‐related adverse events (irAEs) induced
by immune checkpoint inhibitors (ICIs) have been suggested by several studies, their …

Introduction Nivolumab has demonstrated efficacy against metastatic non-small cell lung
cancer (NSCLC). However, immune-related adverse events can occur, among which …